alpha-aminopyridine has been researched along with Growth Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbadessa, G; Bagnulo, R; Bartuli, A; De Luisi, A; Di Tommaso, S; Forte, G; Grossi, V; Lerone, M; Loconte, DC; Melis, D; Peserico, A; Praticò, AD; Ranieri, C; Resta, N; Ruggieri, M; Sanese, P; Schwartz, B; Selicorni, A; Simone, C; Susca, FC; Yu, Y | 1 |
| De Biase, RV; Gnessi, L; Lenzi, A; Lubrano, C; Pascucci, C; Quattrucci, S; Savi, D | 1 |
2 other study(ies) available for alpha-aminopyridine and Growth Disorders
| Article | Year |
|---|---|
In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Topics: Adolescent; Allosteric Regulation; Aminopyridines; Child; Child, Preschool; Class I Phosphatidylinositol 3-Kinases; Female; Fibroblasts; Growth Disorders; Humans; Imidazoles; Male; Mutation; Oncogene Protein v-akt; Primary Cell Culture; Proto-Oncogene Proteins c-akt; Signal Transduction | 2018 |
Impact of CFTR-modulating drugs on GH-IGF-1 axis impairment in adult patients with cystic fibrosis.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Follow-Up Studies; Growth Disorders; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Mutation; Prognosis; Quinolones | 2019 |